(2016). Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care. http://doi.org/10.2337/dc15-1194
. E. Pearson
First name
E.
Middle name
R.
Last name
Pearson
(2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8
. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238
.